Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial

Wen Kuan Huang; Hung Chih Hsu; Tsai Sheng Yang; Chun Wei Lu; Yi Ru Pan; Chiao En Wu; Wen Hung Chung; Shuen Iu Hung; Chun Nan Yeh

doi:10.1016/j.ejca.2023.113286

Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial

Wen Kuan Huang
, Hung Chih Hsu
, Tsai Sheng Yang
, Chun Wei Lu
, Yi Ru Pan
, Chiao En Wu
, Wen Hung Chung
, Shuen Iu Hung
, Chun Nan Yeh^*

^*Corresponding author for this work

School of Medicine

Chang Gung University
Chang Gung Memorial Hospital
National Yang Ming Chiao Tung University

Research output: Contribution to journal › Journal Article › peer-review

1 Scopus citations

Abstract

To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.¹ Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.² Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.^{3, 4} Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1–3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR.⁵ This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102).

Original language	English
Article number	113286
Pages (from-to)	113286
Journal	European Journal of Cancer
Volume	195
DOIs	https://doi.org/10.1016/j.ejca.2023.113286
State	Published - 12 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
Incidence
Zinc
Vascular Endothelial Growth Factor A
Phenylurea Compounds/adverse effects
Protein Kinase Inhibitors/adverse effects
Dietary Supplements

Access to Document

10.1016/j.ejca.2023.113286

Cite this

@article{668112821a9a4109a595d9b5be0fbc48,

title = "Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial",

abstract = "To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35\% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.1 Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.2 Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.3, 4 Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1–3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR.5 This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102).",

keywords = "Humans, Incidence, Zinc, Vascular Endothelial Growth Factor A, Phenylurea Compounds/adverse effects, Protein Kinase Inhibitors/adverse effects, Dietary Supplements",

author = "Huang, \{Wen Kuan\} and Hsu, \{Hung Chih\} and Yang, \{Tsai Sheng\} and Lu, \{Chun Wei\} and Pan, \{Yi Ru\} and Wu, \{Chiao En\} and Chung, \{Wen Hung\} and Hung, \{Shuen Iu\} and Yeh, \{Chun Nan\}",

year = "2023",

month = dec,

doi = "10.1016/j.ejca.2023.113286",

language = "英语",

volume = "195",

pages = "113286",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib

T2 - A phase II randomized clinical trial

AU - Huang, Wen Kuan

AU - Hsu, Hung Chih

AU - Yang, Tsai Sheng

AU - Lu, Chun Wei

AU - Pan, Yi Ru

AU - Wu, Chiao En

AU - Chung, Wen Hung

AU - Hung, Shuen Iu

AU - Yeh, Chun Nan

PY - 2023/12

Y1 - 2023/12

N2 - To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.1 Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.2 Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.3, 4 Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1–3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR.5 This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102).

AB - To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.1 Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.2 Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.3, 4 Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1–3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR.5 This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102).

KW - Humans

KW - Incidence

KW - Zinc

KW - Vascular Endothelial Growth Factor A

KW - Phenylurea Compounds/adverse effects

KW - Protein Kinase Inhibitors/adverse effects

KW - Dietary Supplements

UR - https://www.scopus.com/pages/publications/85177842418

U2 - 10.1016/j.ejca.2023.113286

DO - 10.1016/j.ejca.2023.113286

M3 - 文章

C2 - 37968194

AN - SCOPUS:85177842418

SN - 0959-8049

VL - 195

SP - 113286

JO - European Journal of Cancer

JF - European Journal of Cancer

M1 - 113286

ER -

Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this